39.52
前日終値:
$38.33
開ける:
$38.35
24時間の取引高:
175.49K
Relative Volume:
0.42
時価総額:
$2.26B
収益:
-
当期純損益:
$-80.77M
株価収益率:
-31.12
EPS:
-1.27
ネットキャッシュフロー:
$-80.80M
1週間 パフォーマンス:
+10.43%
1か月 パフォーマンス:
-1.60%
6か月 パフォーマンス:
-19.46%
1年 パフォーマンス:
-6.42%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
39.56 | 2.26B | 0 | -80.77M | -80.80M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
473.61 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
592.96 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
230.10 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
228.81 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
2025-01-17 | アップグレード | Goldman | Neutral → Buy |
2024-11-05 | 再開されました | Wedbush | Outperform |
2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | 開始されました | Oppenheimer | Outperform |
2024-04-02 | 開始されました | Goldman | Neutral |
2024-02-15 | 開始されました | Wolfe Research | Outperform |
2023-12-08 | 開始されました | Citigroup | Buy |
2023-11-02 | 開始されました | Stifel | Buy |
2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
2023-08-31 | 開始されました | Needham | Buy |
2023-06-15 | 開始されました | Barclays | Equal Weight |
2023-05-01 | 開始されました | Guggenheim | Buy |
2023-03-22 | 開始されました | Wedbush | Outperform |
2023-03-09 | 開始されました | BTIG Research | Buy |
2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
2023-02-02 | 開始されました | Bryan Garnier | Buy |
2022-11-11 | 開始されました | Jefferies | Buy |
2022-08-25 | 開始されました | SVB Leerink | Outperform |
2022-07-21 | 開始されました | H.C. Wainwright | Buy |
2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
(MLTX) On The My Stocks Page - news.stocktradersdaily.com
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st
Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq
4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World
Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World
MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle
Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia
MoonLake secures up to $500 million financing; research update - The Pharma Letter
Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada
MoonLake secures $500m for lead drug, plus other financings - pharmaphorum
Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare
MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine
MoonLake secures up to $500M in financing from Hercules Capital - MSN
MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News
MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener
MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord
MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks
MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks
Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener
MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire
MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan
MoonLake (MLTX) Secures $500M Non-Dilutive Financing to Advance Sonelokimab - GuruFocus
How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com
Teacher Retirement System of Texas Has $354,000 Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World
PNC Financial Services Group Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - The AM Reporter
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
大文字化:
|
ボリューム (24 時間):